ArticleNature2023
B-cell-specific checkpoint molecules that regulate anti-tumour immunity.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 118 papers.
0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
25.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 155 citations in OpenAlex.
- Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results.Nature medicine · 2025Trial
- Trial
- CTGF: The remodeler of the tumor immune microenvironment (Review).Oncology reports · 2026Review
- Loss of short-form Ron promotes B and T cell cooperation to prevent outgrowth of breast cancer bone metastasis.bioRxiv : the preprint server for biology · 2026Article
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Gastric cancer tertiary lymphoid structures in the muscularis propria are associated with therapy resistance and promote immunosuppression.Nature communications · 2026Article
- CMTM6 maintains B cell-intrinsic membrane CD40 stability to regulate anti-tumor immunity.Acta pharmaceutica Sinica. B · 2026Article
- Humoral immunity in cancer.Signal transduction and targeted therapy · 2026Review
- Interferon-Mediated Regulation of Memory B Cell Identity and Function.Immunological reviews · 2026Review
- Integrated multi-omics profiling of treatment-naive cervix uteri premalignant lesions and cervical squamous cell carcinoma reveals ecosystem and drivers underlying cervical cancer progression.Cell death & disease · 2026Article
- Review
- Benchmarking the prediction of responding cells to perturbations affecting both gene expression and cellular abundance using scRNA sequencing.Scientific reports · 2026Article
- Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy.Journal for immunotherapy of cancer · 2026Article
- Tumor Anti-Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment.Cancer medicine · 2026Review
- Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer patients.Translational andrology and urology · 2026Article
- Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.International journal of molecular sciences · 2026Review
- TIM-3 in Cardiovascular Disease.Current heart failure reports · 2026Review
- Efferocytosis-related gene PLG in prognosis, immune correlation, and contribution to malignant behavior in vitro and in vivo of clear cell renal cell carcinoma.Scientific reports · 2026Article
- Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial.Cancer immunology research · 2026Article
- TIM-3 in AML: pathogenic roles and therapeutic targetability.Clinical and experimental medicine · 2026Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
27 authors at 5 institutions in 5 countries.
Lloyd BodEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Yoon-Chul KyeEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-0261-5247
Jingwen ShiEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Elena Torlai TrigliaKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-6059-0116
Alexandra SchnellEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-3442-7750
Johannes FesslerEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Stephen M OstrowskiDepartment of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
Max Y Von-FranqueDepartment of Dermatology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-5232-6454
Juhi R KuchrooEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Rocky M BarillaEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-8062-7246
Sarah ZaghouaniEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-4467-6542
Elena ChristianKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Toni Marie DeloreyKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-6614-3803
Kanishka MohibThomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-7332-5530
Sheng XiaoEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Nadine SlingerlandEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-3134-6472
Christopher J GiulianoKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0586-6095
Orr AshenbergKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Zhaorong LiAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5268-6986
David M RothsteinThomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-9455-7971
David E FisherDepartment of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
Orit Rozenblatt-RosenKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-6313-3570
Arlene H SharpeEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-9736-2109
Francisco J QuintanaKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8156-0736
Lionel ApetohEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-2774-438X
Aviv RegevKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA. aviv.regev.sc@gmail.com.ORCID 0000-0003-3293-3158
Vijay K KuchrooEvergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA. vkuchroo@rics.bwh.harvard.edu.ORCID 0000-0001-7177-2110
Broad Institute · USBrigham and Women's Hospital · USMassachusetts General Hospital · USUniversity of Pittsburgh · USUniversité de Tours · FR
Funding
Role of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5MTransgenic / Knock-out mouse coreP01AI073748 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BEHAR, SAMUEL M · 2008 to 2019
$17.1MTranslational Core (Expression Core)P01AI129880 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROTHSTEIN, DAVID M · 2018 to 2022
$9.4MRole of Tim-3:Bat-3 pathway in inducing tolerogenic DCs and peripheral toleranceR01AI144166 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI VIJAY K. KUCHROO · 2020 to 2026
$3.2MNIAID NIH HHS P01 AI039671NIAID NIH HHS P01 AI056299NIAID NIH HHS P01 AI073748NIAID NIH HHS P01 AI129880NIAID NIH HHS R01 AI144166
Abstract
The role of B cells in anti-tumour immunity is still debated and, accordingly, immunotherapies have focused on targeting T and natural killer cells to inhibit tumour growth
Indexed as
B-LymphocytesMelanomaAnimalsAntigen PresentationFlow CytometryHepatitis A Virus Cellular Receptor 1Interferon Type ILymph NodesLymphocyte ActivationLymphocyte Activation Gene 3 ProteinMelanoma, ExperimentalMiceReceptors, Antigen, B-CellReceptors, ImmunologicSingle-Cell Gene Expression AnalysisT-LymphocytesHavcr1 protein, mouseHepatitis A Virus Cellular Receptor 1Interferon Type ILag3 protein, mouseLymphocyte Activation Gene 3 ProteinReceptors, Antigen, B-CellReceptors, ImmunologicT cell Ig and ITIM domain protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.